Ivonescimab Shows Promise in Squamous Non-Slight Cell Lung Cancer Treatment

A novel study, HARMONi-6, demonstrates that the combination of ivonescimab and chemotherapy significantly improves progression-free survival compared to tislelizumab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC). This represents a potential advancement in managing a particularly aggressive form of lung cancer.

Understanding Squamous Non-Small Cell Lung Cancer

Squamous NSCLC is a subtype of lung cancer associated with poorer clinical outcomes than non-squamous NSCLC. Treatment options have historically been limited, making the findings from the HARMONi-6 trial particularly significant.

The HARMONi-6 Trial: A Detailed Appear

The HARMONi-6 trial was a randomized, double-blind, phase 3 clinical trial conducted across 50 sites in China. It involved 761 patients aged 18-75 with previously untreated, unresectable stage IIIB, IIIC, or stage IV squamous NSCLC and a good performance status (Eastern Cooperative Oncology Group score of 0 or 1). [1]

Patients were randomly assigned to receive either:

• Ivonescimab (20 mg/kg) plus chemotherapy (paclitaxel and carboplatin)
• Tislelizumab (200 mg) plus chemotherapy (paclitaxel and carboplatin)

Both groups received treatment every three weeks for four cycles, followed by maintenance therapy with either ivonescimab or tislelizumab alone for up to 24 months. Randomization was stratified by disease stage and PD-L1 tumor proportion score. [1]

Key Findings: Progression-Free Survival Improvement

The trial’s primary endpoint was progression-free survival (PFS). Interim analysis revealed a statistically significant and clinically meaningful improvement in PFS with ivonescimab plus chemotherapy.

• Median PFS (Ivonescimab + Chemo): 11.1 months [3]
• Median PFS (Tislelizumab + Chemo): 6.9 months [3]
• Hazard Ratio: 0.60 (95% CI: 0.46–0.78, P < .0001) [3]

The benefits of ivonescimab were observed across different PD-L1 expression levels, including patients with low PD-L1 expression (TPS < 1%), where the median PFS was 9.9 months compared to 5.7 months with tislelizumab. [3]

How Ivonescimab Works

Ivonescimab is a first-in-class bispecific antibody that simultaneously targets PD-1 and vascular endothelial growth factor (VEGF). [2] By blocking PD-1, it restores the activity of antitumor T-cells. Inhibiting VEGF normalizes tumor blood vessels, reduces hypoxia, and enhances immune cell infiltration, creating a more favorable environment for immunotherapy. [2]

Looking Ahead

The HARMONi-6 trial, presented at the ESMO Congress 2025, represents a significant step forward in the treatment of advanced squamous NSCLC. [2] Further research will continue to evaluate the long-term benefits and safety of ivonescimab in combination with chemotherapy.